Regonat 40mg Tablet

Regonat 40 mg tablet is used in the treatment of:
1. Colorectal cancer has started to spread to other parts of the body
2. Gastrointestinal stromal tumors (GIST) (a type of stomach and bowel cancer)
3. Liver cancer in adult patients who have already undergone treatment with Sorafenib

The human body shows undesired symptoms after taking Regonat 40mg Tablet. Usually, they disappear with time as the body adjusts to the medicine. These side effects don't need special medical attention. It is advised to consult your doctor if these symptoms become unmanageable.

Some of the common side effects of Regonat Tablet are mentioned below:

Rash

Fever

Hair loss

Diarrhea

Infection

Body pain

Weakness

Headache

Weight loss Low appetite

Changed voice

Low blood count

Nausea & Vomiting

High Blood pressure

Infection of the stomach

Inflammation of the mouth

Unusual bleeding and bruising

Increased level of liver enzymes

Low levels of platelets and WBCs, Severe side effects

Chest pain

Thyroid problem

Bilirubin in urine

Skin detachment

Secondary cancer

Severe allergic reactions

High level of uric acid in the blood

Regonat 40mg Tablet is a prescription-based anticancer drug that should be administered orally. It is advised to take this tablet after consulting your healthcare expert.

Regonat 40mg Tablet is an anticancer medicine that belongs to the drug class of Tyrosine kinase inhibitors. This drug inhibits the formation of blood vessels that are responsible for the blood supply to the tumor cells. That’s how it slows down and stops the growth of cancer cells and also prevents their spread to nearby organs.

It is advised not to miss any scheduled dosage of Regonat 40mg Tablet. In case you miss a dose, consult your doctor immediately.
Don't overdose to compensate for the missed one. Contact your doctor or any healthcare provider and seek medical attention immediately in such cases.

It is advised to use effective birth control ways and avoid pregnancy during the treatment with Regonat 40mg Tablet.
A person should avoid smoking while undergoing treatment with Regonat 40mg Tablet. Smoking may reduce the effectiveness of medicine.
Monitor your blood sugar & pressure, Kidney & Liver function (KFT & LFT), Heart function at proper intervals after taking Regonat 40mg Tablet.
Skin becomes extremely sensitive after taking Regonat 40mg Tablet. It is advised to cover your skin exposed to direct sun rays and use high SPF sunscreen before going out.
It is advised to avoid taking analgesics/ antacids (medicines used to neutralize the stomach acid) while taking Regonat 40mg Tablet, as it may reduce the effectiveness of the medicine.
Keep your body hydrated as Diarrhea is one of the common side effects experienced after taking Regonat 40mg Tablet. Consult your doctor if it doesn't stop or if blood appears in your stools.
If you experience any kind of symptoms after taking Regonat 40mg Tablet like unexplained bruising or bleeding, sore throat, mouth ulcers, high temperature (fever), or other signs of infection, it is important to Inform your doctor as soon as possible.

At our pharmacy, your health is our top priority. All of our medicines are safe, effective, and approved by leading health authorities. We partner exclusively with reliable and reputable manufacturers, ensuring the highest quality standards in every product we deliver.

Enjoy the convenience of fast home delivery, secure packaging, and affordable prices—plus special discounts on bulk orders. We’re proud to offer international shipping to a wide range of countries across Asia, Europe, Africa, the Americas, and beyond, making trusted healthcare accessible no matter where you are.

Whether you're a patient or a healthcare provider, you can order with confidence and compassion. Our goal is to ensure that quality healthcare reaches everyone, everywhere.


We currently ship to:

Barbados, Haiti, Trinidad and Tobago, Mexico, Bahamas, Ecuador, Peru, Chile, Brazil, Colombia, Philippines, U.K., USA, Kuwait, Saudi Arabia, UAE, Oman, Qatar, Japan, Ireland, Russia, China, France, Australia, Lithuania, Nigeria, Romania, Algeria, Canada, Singapore, Thailand, Hong Kong, Bahrain, Jordan, Indonesia, Hungary, Moldova, Bulgaria, Azerbaijan, Congo, Ethiopia, Lebanon, Morocco, Mozambique, South Korea, Sri Lanka, Belarus, Mongolia, Malaysia, Vietnam, Tunisia, Zambia, and Israel.
Experience the quality everyone’s talking about – order today!

Kato, T., Kudo, T., Kagawa, Y., Murata, K., Ota, H., Noura, S. & Eguchi, H. (2023). Phase II dose titration study of regorafenib in progressive unresectable metastatic colorectal cancer. Scientific Reports, 13(1), 2331.
Ma, W., Li, Y., Lu, Y., Liang, Z., Yu, H., Han, J. & Cheng, J. (2025). A Multicenter Retrospective Study: Impact of First-Line Treatment Strategies on Second-Line Efficacy and Safety of Regorafenib with or Without PD-1 Inhibitors in Unresectable Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma, 2123-2137.
Skårderud, M. R., Polk, A., Vistisen, K. K., Larsen, F. O., & Nielsen, D. L. (2022). Efficacy and safety of regorafenib in the treatment of metastatic colorectal cancer: a systematic review. Cancer treatment reviews, 62, 61-73.
Yan, T., Huang, C., Peng, C., Duan, X., Ji, D., Duan, Y.& Lu, Y. (2023). A multi-center retrospective study on the efficacy and safety of regorafenib vs. regorafenib combined with PD-1 inhibitors as a second-line therapy in patients with advanced hepatocellular carcinoma. Annals of Translational Medicine, 11(2), 109.
Zhang, W., Zhao, Y., Ma, G., Zhang, Y., Guo, Y., & Chen, Z. (2023). Efficacy and safety of regorafenib alone or in combinations in the second-line setting for advanced hepatocellular carcinoma: A multicenter real-world study. Journal of Gastrointestinal Oncology, 12(4), 1549.
Zhao, J., Guo, Y., Feng, T., Rong, D., Kong, X., Huang, T. & Xia, Y. (2023). Efficacy and safety of regorafenib in combination with immune checkpoint inhibitor therapy as second-line and third-line regimen for patients with advanced hepatocellular carcinoma: A retrospective study. Journal of Gastrointestinal Oncology, 14(6), 2549.